Published by mark itwired
Posted on September 3, 2021
Hypoparathyroidism is a rare endocrine disorder, which often results in levels of calcium and high levels of phosphate, which in turn results in the production of low or abnormal parathyroid (PTH) levels. According to a recent research report by Future Market Insights (FMI), the hypoparathyroidism treatment market is estimated to reach a valuation of US$ 717.7 Mn in 2021, and is projected to display a promising CAGR of approximately 8% through the end of the forecast period in 2031.
Hypothyroidism primarily arises from surgeries in the neck region. It is associated to accidental damage to the parathyroid gland. High prevalence of these surgeries is expected to boost the demand in the hypoparathyroidism treatment market. For instance, in the U.S., up to 115,000 people are diagnosed with the chronic hypoparathyroidism. The majority of the hypoparathyroidism cases are caused by anterior neck surgery, which accounts for up to 75% of the of all hypoparathyroidism cases. The remaining 25% cases are non-surgical or in very rare cases is linked to genetic disorders.
Furthermore, considering the rare occurrence of this medical condition, hypoparathyroidism has been designated as an orphan disease by the U.S. FDA and European Commission. This designation of orphan disease will help manufacturers to speed up their drug development processes, which leads to better availability of drugs for treatments of hypoparathyroidism.
However, the unprecedented nature of the COVID-19 pandemic has had a significant impact on the development of drugs for rare diseases including those associated with hypoparathyroidism. Preference now is being given to the development of life-savings drugs with greater focus on development of COVID-19 drugs and vaccines, thus halting or suspending existing clinical trials other than live saving drugs.
Also, this has led to the delay or postponement of enrolment of the new participants for clinical studies. Thus, the lack of sufficient data availability on the safety and effectiveness of treatments from clinical trials, will hurt short-term prospects. Clinical trials will gradually resume through 2021, and is anticipated to pick up pace during the forecast period.
Get Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857
Calcium supplements dominate the hypoparathyroidism treatment market growing 2x by 2031 owing to efficacy with hormonal therapy.
Parenteral route of administration is projected to grow at higher pace, driven by a rise in the number of clinical trials, and approval of new drugs which are influencing strong growth in this segment.
United States holds over 85% of the North America market for hypoparathyroidism treatments and will remain dominant owing to government incentives.
The U.K. will exhibit high demand, registering y-o-y growth at nearly 7% in 2021.
Germany and France will emerge as key markets within Europe.
China and India reflect high potential for growth on the back of a large subclinical patient pool for kidney disorders, diabetes, obesity, thyroid surgeries or head & neck surgery.
Growing cases of hypoparathyroidism and associated neck surgeries, coupled with an increase in patient awareness and screening, faster approvals and grants for product development, and favourable reimbursement scenarios, are major factors influencing market growth. Demand for biologics and the emergence of personalized medicine are some of the upcoming trends that are expected to generate significant growth opportunities for manufacturers operating in this space,” says the FMI Analyst
Prominent players in the hypoparathyroidism treatment market are focusing on receiving approvals and grants for the development of new drugs to cater to the growing cases of hypoparathyroidism, thus, enhancing their market presence. For instance,
In October 2020, Ascendis’s TransCon PTH was designated as orphan drug by the European commission (EC), which is approved for use to treat hypoparathyroidism in Europe.
In July 2020, ProLynx, received a Small Business Innovation Research (SIBR) grant from NIH to help fasten the development PTH (1, 34), a long-acting parathyroid hormone that can be in a week to patients suffering from hypoparathyroidism.
Prominent players in the hypoparathyroidism treatment market is entering into the strategic agreements and collaborations at regional levels, with special focus on emerging economies. Major players are consolidating their positions through regional collaborations to strengthen their presence and increase their product reach in these countries.
Some of the leading market players covered by FMI in the hypoparathyroidism market include
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global hypoparathyroidism treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Hypoparathyroidism treatment market on the basis of product type (parathyroid hormone, vitamin D analogues, and calcium supplements), route of administration (oral, parenteral), and distribution channel (hospital pharmacy, retail pharmacy, and online sales) across four major regions.
Request TOC of the Report @ https://www.futuremarketinsights.com/reports/hypoparathyroidism-treatment-market/table-of-content
Which is the most lucrative market for hypoparathyroidism treatment?
The U.S. currently leads the global market for hypoparathyroidism treatment, and demand will be significant throughout the forecast period. Growing number thoracic surgeries, and high prevalence of hypoparathyroidism are some of the key factors contributing to the higher demand.
Which is the Key Hypoparathyroidism Treatment Product Type?
Vitamin D analogue for vitamin D analogue (vitamin D2&D3) hold significant share in the hypoparathyroidism treatment market. The demand is expected to remain high in the near future, especially due to preference among physician as a first line of treatment owing to its convenience of oral administration.
Which are the Leading Companies Operating in the Hypoparathyroidism Treatment Market?
Some of the prominent players offering drugs for hypoparathyroidism include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, ProLynx Inc, Amgen, Inc. EnteraBio Ltd, and Ascendis Pharma A/S
What are the key factors that hindering the growth of the hypoparathyroidism treatment market?
Limited availability of hormonal therapy (NATPARA) due to adverse side effects is the key restraint for market growth. Apart from this high treatment cost and product recalls are some the factors having negative impact on the market growth.
The post Hypoparathyroidism Treatment Market is projected to expand at a CAGR close to 8% through 2031 | FMI first appeared on Market Research Blog.
Hypoparathyroidism is a rare endocrine disorder, which often results in levels of calcium and high levels of phosphate, which in turn results in the production of low or abnormal parathyroid (PTH) levels. According to a recent research report by Future Market Insights (FMI), the hypoparathyroidism treatment market is estimated to reach a valuation of US$ 717.7 Mn in 2021, and is projected to display a promising CAGR of approximately 8% through the end of the forecast period in 2031.
Hypothyroidism primarily arises from surgeries in the neck region. It is associated to accidental damage to the parathyroid gland. High prevalence of these surgeries is expected to boost the demand in the hypoparathyroidism treatment market. For instance, in the U.S., up to 115,000 people are diagnosed with the chronic hypoparathyroidism. The majority of the hypoparathyroidism cases are caused by anterior neck surgery, which accounts for up to 75% of the of all hypoparathyroidism cases. The remaining 25% cases are non-surgical or in very rare cases is linked to genetic disorders.
Furthermore, considering the rare occurrence of this medical condition, hypoparathyroidism has been designated as an orphan disease by the U.S. FDA and European Commission. This designation of orphan disease will help manufacturers to speed up their drug development processes, which leads to better availability of drugs for treatments of hypoparathyroidism.
However, the unprecedented nature of the COVID-19 pandemic has had a significant impact on the development of drugs for rare diseases including those associated with hypoparathyroidism. Preference now is being given to the development of life-savings drugs with greater focus on development of COVID-19 drugs and vaccines, thus halting or suspending existing clinical trials other than live saving drugs.
Also, this has led to the delay or postponement of enrolment of the new participants for clinical studies. Thus, the lack of sufficient data availability on the safety and effectiveness of treatments from clinical trials, will hurt short-term prospects. Clinical trials will gradually resume through 2021, and is anticipated to pick up pace during the forecast period.
Get Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857
Calcium supplements dominate the hypoparathyroidism treatment market growing 2x by 2031 owing to efficacy with hormonal therapy.
Parenteral route of administration is projected to grow at higher pace, driven by a rise in the number of clinical trials, and approval of new drugs which are influencing strong growth in this segment.
United States holds over 85% of the North America market for hypoparathyroidism treatments and will remain dominant owing to government incentives.
The U.K. will exhibit high demand, registering y-o-y growth at nearly 7% in 2021.
Germany and France will emerge as key markets within Europe.
China and India reflect high potential for growth on the back of a large subclinical patient pool for kidney disorders, diabetes, obesity, thyroid surgeries or head & neck surgery.
Growing cases of hypoparathyroidism and associated neck surgeries, coupled with an increase in patient awareness and screening, faster approvals and grants for product development, and favourable reimbursement scenarios, are major factors influencing market growth. Demand for biologics and the emergence of personalized medicine are some of the upcoming trends that are expected to generate significant growth opportunities for manufacturers operating in this space,” says the FMI Analyst
Prominent players in the hypoparathyroidism treatment market are focusing on receiving approvals and grants for the development of new drugs to cater to the growing cases of hypoparathyroidism, thus, enhancing their market presence. For instance,
In October 2020, Ascendis’s TransCon PTH was designated as orphan drug by the European commission (EC), which is approved for use to treat hypoparathyroidism in Europe.
In July 2020, ProLynx, received a Small Business Innovation Research (SIBR) grant from NIH to help fasten the development PTH (1, 34), a long-acting parathyroid hormone that can be in a week to patients suffering from hypoparathyroidism.
Prominent players in the hypoparathyroidism treatment market is entering into the strategic agreements and collaborations at regional levels, with special focus on emerging economies. Major players are consolidating their positions through regional collaborations to strengthen their presence and increase their product reach in these countries.
Some of the leading market players covered by FMI in the hypoparathyroidism market include
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global hypoparathyroidism treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Hypoparathyroidism treatment market on the basis of product type (parathyroid hormone, vitamin D analogues, and calcium supplements), route of administration (oral, parenteral), and distribution channel (hospital pharmacy, retail pharmacy, and online sales) across four major regions.
Request TOC of the Report @ https://www.futuremarketinsights.com/reports/hypoparathyroidism-treatment-market/table-of-content
Which is the most lucrative market for hypoparathyroidism treatment?
The U.S. currently leads the global market for hypoparathyroidism treatment, and demand will be significant throughout the forecast period. Growing number thoracic surgeries, and high prevalence of hypoparathyroidism are some of the key factors contributing to the higher demand.
Which is the Key Hypoparathyroidism Treatment Product Type?
Vitamin D analogue for vitamin D analogue (vitamin D2&D3) hold significant share in the hypoparathyroidism treatment market. The demand is expected to remain high in the near future, especially due to preference among physician as a first line of treatment owing to its convenience of oral administration.
Which are the Leading Companies Operating in the Hypoparathyroidism Treatment Market?
Some of the prominent players offering drugs for hypoparathyroidism include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, ProLynx Inc, Amgen, Inc. EnteraBio Ltd, and Ascendis Pharma A/S
What are the key factors that hindering the growth of the hypoparathyroidism treatment market?
Limited availability of hormonal therapy (NATPARA) due to adverse side effects is the key restraint for market growth. Apart from this high treatment cost and product recalls are some the factors having negative impact on the market growth.
The post Hypoparathyroidism Treatment Market is projected to expand at a CAGR close to 8% through 2031 | FMI first appeared on Market Research Blog.
Explore more articles in the Research Reports category
